Insud Pharma expands its presence in the health sector. The Spanish pharmaceutical group appointed two of its directors as joint administrators of the company specialized in women’s health, eCareYou Innovation. Since last October 23, Helen Tomlinson and Tomos Shillingford, global president of Exeltis Consumer Healthcare and general counsel from Insud, hold separate positions at eCareYou.
The appointments of Tomlinson and Shillingford coincide with the revocation of companies managed by Emma Molera Massa and Dolores López Martínezco-founder and general director and executive director of eCareYou, together with the company of Joan Garriga Rodó, owner of the Joga Pro marketing agency.
The company, which now manages Insud Pharma, was created in 2015 in Barcelona as start up. Currently, its products are present on all five continents. Emma Molera has twelve years of experience at Omega Pharmawhere she became general director, a company in which she coincided with Dolors López, who then held the position of marketing director.
Insud Pharma restructured its balance sheet with an increase of 9.9 million euros
Omega Pharma was a Belgian company founded in 1987 that acquired the American Perrigo in 2014, when it had turnover of 1,270 million euros. This stopped operating with its founding brand in 2015 when it became the division of brand consumer health by Perrigo. The year of its dissolution coincides with the start of activities of eCare You Innovation.
In September it was learned that Insud Pharma had carried out a capital increase worth nearly 9.9 million euros, signed on June 30 and published in the commercial registry on August 27. With this operation, The resulting amount subscribed amounted to more than 10.2 million euros.
After the expansion, The nominal value of the 366,339 social shares of Insud Pharma went from one euro to 28 euros. Company sources then explained to PlantaDoce that it was not an additional disbursement, but rather a capitalization of voluntary reserves. “It is only an accounting reclassification, so it does not change the company’s own funds,” they pointed out from the pharma.
